We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

138 hedge funds and large institutions have $183M invested in Nektar Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 37 increasing their positions, 34 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

691% more call options, than puts

Call options by funds: $182K | Put options by funds: $23K

29% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 17

9% more capital invested

Capital invested by funds: $168M → $183M (+$15M)

4% more funds holding

Funds holding: 133 → 138 (+5)

9% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 34

0.19% more ownership

Funds ownership: 4.91% → 5.1% (+0.19%)

Holders
138
Holders Change
+5
Holders Change %
+3.76%
% of All Funds
1.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
37
Reduced
34
Closed
17
Calls
$182K
Puts
$23K
Net Calls
+$159K
Net Calls Change
+$186K

Top Buyers

1
EAM
Eventide Asset Management
Massachusetts
+$2.38M
2
BCM
Bridgeway Capital Management
Texas
+$1.73M
3
WP
Woodline Partners
California
+$1.41M
4
Northern Trust
Northern Trust
Illinois
+$1.21M
5
BlackRock
BlackRock
New York
+$1.03M

Top Sellers

1
DTC
Deep Track Capital
Connecticut
-$2.48M
2
Morgan Stanley
Morgan Stanley
New York
-$923K
3
GCP
GSA Capital Partners
United Kingdom
-$911K
4
Two Sigma Investments
Two Sigma Investments
New York
-$567K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$426K
Name Holding Trade Value Shares
Change 		Change in
Stake
UOC
26
UBS O'Connor
Illinois
$1.5M +$136K +7,127 +10%
AI
27
Acuitas Investments
Washington
$1.43M +$275K +14,436 +25%
AC
28
Armistice Capital
New York
$1.3M +$208K +10,934 +20%
AC
29
Almitas Capital
California
$1.2M – – –
JP Morgan Chase
30
JP Morgan Chase
New York
$1.19M +$770K +40,404 +197%
CM
31
CM Management
Florida
$975K – – –
Morgan Stanley
32
Morgan Stanley
New York
$970K -$923K -48,434 -49%
Connor, Clark & Lunn Investment Management (CC&L)
33
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$846K +$44K +2,306 +6%
Invesco
34
Invesco
Georgia
$841K +$3.3K +173 +0.4%
Dimensional Fund Advisors
35
Dimensional Fund Advisors
Texas
$654K -$15K -785 -2%
AQR Capital Management
36
AQR Capital Management
Connecticut
$627K +$637K +33,439 New
Wellington Management Group
37
Wellington Management Group
Massachusetts
$615K +$601K +31,539 New
Bank of New York Mellon
38
Bank of New York Mellon
New York
$533K -$179K -9,415 -26%
Fidelity Investments
39
Fidelity Investments
Massachusetts
$503K +$394K +20,655 +403%
Barclays
40
Barclays
United Kingdom
$466K +$223K +11,706 +96%
BFM
41
Boothbay Fund Management
New York
$454K – – –
N
42
Nuveen
North Carolina
$425K -$29.5K -1,546 -7%
Balyasny Asset Management
43
Balyasny Asset Management
Illinois
$390K +$46.1K +2,419 +14%
Ameriprise
44
Ameriprise
Minnesota
$366K -$13.1K -689 -4%
ECM
45
ExodusPoint Capital Management
New York
$364K +$356K +18,691 New
Macquarie Group
46
Macquarie Group
Australia
$333K – – –
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$311K +$288K +15,118 +1,878%
Bank of America
48
Bank of America
North Carolina
$284K +$46K +2,415 +20%
GCP
49
GSA Capital Partners
United Kingdom
$279K -$911K -47,780 -77%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$238K -$2.52K -132 -1%
1
2
3 4 5

NKTR Hedge Fund Activity: Q3 2024 in Review

138 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2024, worth a combined $183M — up 8.9% from $168M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new NKTR positions and 17 closed out — a net gain of 5 holders — while 37 added to existing stakes and 34 trimmed.

The largest buyer was Eventide Asset Management, adding an estimated $2.38M. The largest seller was Deep Track Capital, cutting an estimated $2.48M.

  • 138 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2024, up from 133 in Q2 2024.
  • Funds reported $183M of Nektar Therapeutics stock for Q3 2024, up 8.9% quarter-over-quarter.
  • 22 funds opened new Nektar Therapeutics positions in Q3 2024 and 17 closed out, a net change of +5 holders.
  • The largest Nektar Therapeutics buyer in Q3 2024 was Eventide Asset Management, an estimated $2.38M added.
  • The largest Nektar Therapeutics seller in Q3 2024 was Deep Track Capital, an estimated $2.48M sold.

Based on aggregated 13F filings for Q3 2024.